1 per kilogram of body weight was administered
bimonthly.
2 ation 1 and 2 trials showed that monthly and
bimonthly aflibercept were noninferior to monthly ranibi
3 sts, donor-type cells in blood were measured
bimonthly and the resulting repopulation kinetics were g
4 tory of Depressive Symptoms was administered
bimonthly,
and rates of clinically significant symptom e
5 s (0.36-2.5 x 10E7 MSCs/infusion) or placebo
bimonthly at the time of study enrollment.
6 d discomfort 36 hours after she received her
bimonthly dose of subcutaneous adalimumab.
7 nt was done at baseline, post-treatment, and
bimonthly during the maintenance period from 8 to 12 mon
8 (MRI) of the brain were obtained before and
bimonthly during treatment to evaluate responses.
9 in plus fluorouracil/leucovorin administered
bimonthly (
FOLFOX4) in patients age younger than and at
10 ent with monthly (months 3-5) and subsequent
bimonthly follow-up (months 6-18).
11 ipants completed 140 baseline visits and 390
bimonthly follow-up visits.
12 The double-blind phase entailed 15
bimonthly followup visits; intervisit adherence data wer
13 precision, we analyzed soybeans and soymilk
bimonthly for within-day precision and over 4 d for day-
14 and wheeze in the children were ascertained
bimonthly from the first 2 to 3 mo of life.
15 o 17 years underwent baseline assessment and
bimonthly guideline-based management visits over 1 year.
16 e Ohio SLE Study were tested at prespecified
bimonthly intervals within windows of +/-1 week.
17 bin, and red cell indexes were determined at
bimonthly intervals.
18 ng Mania Rating Scale (YMRS) at baseline and
bimonthly intervals.
19 Subjects underwent
bimonthly magnetic resonance angiography (Siemens 1.5 T)
20 ebo for 8 weeks, and then were studied using
bimonthly MRI and histologic analysis.
21 n IV infusion (10-40 mg/kg) given monthly or
bimonthly,
or as an SC injection (5 mg/kg) every 2 weeks
22 53), matched by race and age, were followed
bimonthly over 6 mo postpartum.
23 s maintained with an additional 12 months of
bimonthly ranibizumab PRN treatment.
24 Complete
bimonthly releases and daily updates of the GenBank data
25 Complete
bimonthly releases and daily updates of the GenBank data
26 Complete
bimonthly releases and daily updates of the GenBank data
27 Complete
bimonthly releases and daily updates of the GenBank data
28 Complete
bimonthly releases and daily updates of the GenBank data
29 Complete
bimonthly releases and daily updates of the GenBank data
30 Complete
bimonthly releases and daily updates of the GenBank data
31 Complete
bimonthly releases and daily updates of the GenBank data
32 Complete
bimonthly releases and daily updates of the GenBank data
33 Complete
bimonthly releases and daily updates of the GenBank data
34 Complete
bimonthly releases and daily updates of the GenBank data
35 Complete
bimonthly releases and daily updates of the GenBank data
36 Complete
bimonthly releases and daily updates of the GenBank data
37 Complete
bimonthly releases and daily updates of the GenBank data
38 ceive usual care, a behavioral intervention (
bimonthly tailored, nurse-administered telephone interve
39 Wheeze was determined using
bimonthly telephone questionnaires.
40 ention occurred biweekly the first 6 months,
bimonthly thereafter.
41 usly (SC) weekly for 4 weeks, at week 8, and
bimonthly thereafter.
42 general health-related educational materials
bimonthly through the mail.
43 Bimonthly treatment occurred in 15/21 patients (71 %).
44 val [CI], 4.9-8.3), and after institution of
bimonthly treatment the mean change in BCVA at month 12
45 scularly (IM) biweekly for 4 weeks, and then
bimonthly until disease progression.
46 Outcome data were updated
bimonthly until pregnancy, fertility treatment, loss to